The incidence of subcutaneous metastasis from a visceral malignancy, excluding malignant melanoma, lymphoma, and leukemia, is rare with an incidence of 5.3%.
INTRODUCTION
The incidence of subcutaneous metastasis from a visceral malignancy, excluding malignant melanoma, lymphoma, and leukemia, is rare with an incidence of 5.3%. 1 Skin involvement as the presenting sign of a silent internal malignancy is an even rarer event occurring in approximately 0.8%. 2 We report a rare case of a patient who presented to his dermatologist complaining of rapidly developing subcutaneous nodules which subsequently proved to be metastatic colon cancer, and we provide a review of the literature.
CASE REPORT
A 39-year-old man presented to a local dermatologist, with symptoms of multiple subcutaneous nodules over the anterior chest wall and 
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ABSTRACT
Skin metastases from colorectal carcinoma are rare and signal advanced disease. Skin metastasis refers to growth of cancer cells in the skin originating from an internal cancer. In most cases, cutaneous metastasis develops after the initial diagnosis of the primary internal malignancy and late in the course of the disease. In very rare cases, skin metastasis may occur at the same time or before the primary cancer has been discovered and may be the prompt for further thorough investigation. The incidence of skin metastasis varies but is somewhere between 3-10% in patients with a primary malignant tumor. Most common ones are melanoma 
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Subcutaneous nodules, Metastatic, Colon cancer forehead for 3 months (figure 1). The patient also had history of significant weight loss and loss of appetite since last 3 months. He also had history of intermittent constipation lasting for 3-4 days since last 2 months. Fine needle aspiration cytology from skin nodules showed malignant cells with hyperchromatic nuclei, prominent nucleoli, and scanty cytoplasm, with some cells showing intracellular mucin collection suggestive of metastatic mucinous adenocarcinoma (figure 2). For expert opinion this patient came to our Cancer Care Centre.
On examination his vital signs were stable with performance status of 1. His weight was 40 kgs, with emaciated, cachectic look and there was marked pallor. There was no associated lympadenopathy, icterus, or pedal edema. Multiple subcutaneous nodules were noted over the anterior abdominal wall, anterior chest wall, and forehead with size of 1-2 cm, firm too hard in consistency and non-tender (figure 1). There was no history of any bleeding per rectum, but the patient used to have altered bowel habits in the form of intermittent constipation.
Complete blood count showed hemoglobin of 8 gr/dL, with normal leukocyte count of 5300 per cumm and platelet count of 350,000 per cumm. Carcinoembryonic antigen was 480 IU/mL. Peripheral smear was suggestive of dimorphic anemia with MCV of 97 pg/mL. Contrast enhanced computed tomography (CT) of the abdomen showed asymmetrical circumferential thickening with luminal narrowing of caecum and ascending colon, extending to involve luminal narrowing of ascending colon near hepatic flexure with mild ascites without any evidence of liver metastasis (figure 3). Colonoscopy was done and biopsy samples were taken from the right sided ascending colonic mass. Histopathological image showed malignant cells with abundant mucinous cytoplasm and vesicular nuclei with hyperchromatism and prominent nucleoli. Tumor cells were arranged in glandular pattern with intraglandular mucin collection (figure 4). The patient was managed with blood transfusion, hematinics, and palliative right sided hemicolectomy in view of intermittent constipation. Postoperative chemotherapy with 5-fluorouracil, leucovorin, and oxiliplatin (FOLFOX) regimen was started and the patient is under regular treatment at our centre until date. Total 16 cycles of FOLFOX chemotherapy was completed without any major side effects except for the mild grade peripheral neuropathy. All the subcutaneous lesions have been regressed after 3 months of treatment and the current CEA(Carcinoembryonic antigen) is 56 IU/mL.
DISCUSSION
Colorectal carcinoma most often metastasizes to liver and lung, while subcutaneous or skin metastases are rare, accounting for only 5% of such cases. 3, 4 Usually, for al- most all cancers, skin involvement is synonymous with extensive disease and frequently implies a poor prognosis. In colorectal cancer, this event occurs mostly on the incision scars, but is also seen on the skin of the extremities, head and neck, and penis. 5, 6 Cutaneous metastasis may occur through lymphogenous spread, intravascular dissemination, direct extension of tumor, and surgical implantation. 7 Wong and colleagues added the spread along embryonal remnants such as the urachus to the aforementioned mechanisms. 8 With the current knowledge on molecular biology, there is not only the possibility of passive dissemination pathway, known as "tumor embolization", but also an easier way through the processes of angiogenesis and angiolymphatic growth factors that help to increase the total surface of blood vessels for tumor cell invasion. Following the blood vessel invasion, tumor cells that resist to the mechanic stress of circulation and to the immune system "colonize" the subcutaneous tissues until they acquire the necessary angiogenic properties and a favorable microenvironment to leave the state of "numbness". 9 It usually presents as violaceous to flesh-colored, firm, freely mobile, painless nodules, single or multiple (as inour case). It can sometimes mimic epidermal cysts, neurofibromas, lipomas, cicatricial morphea-like plaques, lymphoma, and alopecia. Survival after diagnosis of cutaneous metastasis ranges from 1 to 34 months. The average survival of patients after diagnosis of skin metastasis from colon cancer is, according to Lookingbill and co-workers, 18 months.
Wide local excision of the cutaneous metastatic lesion is the preferred treatment option in isolated lesions. In cases of extensive cutaneous metastases treatment is only palliative. No clear guidelines exist for an optimum chemotherapeutic regimen. The treatment of metastatic colorectal cancer has become increasingly complex and nuanced as treatments have evolved over the last decade. During that time, treatment has evolved from single agent 5-fluorouracil to combination chemotherapy and more recently the inclusion of monoclonal antibodies such as bevacizumab, aflibercept, ramucirumab, regorafenib, cetuximab, panitumab and recently immunotherapy with pembrolizumzb. As such, metastatic colorectal cancer is evolving into a chronic disease in which the median overall survival is in excess of 2 years and the 5-year survival is 10%. Established chemotherapy include 5-fluorouracil, capecitabine, irinotecan, oxiliplatin, and cisplatin. Combinations of irinotecan to bolus 5-fluorouracil, oxaliplatin to infusional 5-fluorouracil, and leucovorin (FOLFOX) or infusional 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) has increased survival to over 20 months. Treating patients sequentially with FOLFIRI followed by FOLFOX, or with FOLFOX followed by FOLFIRI, has increased the median survival times to 21.5 months and 20.6 months, respectively. primary cancer is a rare event. When present, the metastasis usually signifies disseminated disease and poor prognosis. Further analysis of the biology of this mode of metastasis may shed light on mechanisms of metastasis to specific organs, and hopefully these findings will provide targets for novel targeted therapeutic intervention.
ETHICAL APPROVAL There is nothing to be declared.
CONFLICT OF INTEREST
The authors declare no conflict of interest related to this work.
